Centre Leon Berard - Centre regional de lutte contre le cancer Rhone-Alpes

Lyon, Other 69373

0 studies enrolling now · 2 studies all time

What they study most

HER2-positive Breast Cancer, Metastatic Colorectal Adenocarcinoma

Studies at this site

• A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer — Running, not enrolling
• Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer — Completed